Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-465-2 | CAS number: 121-33-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Thirty seven studies of validity 2 (published data and reports) were reported. Negative results were obtained in Ames tests.
Negative in gene mutations and chromosomal aberrations with and without metabolic activation system.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Genetic toxicity in vivo
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Additional information
Genotoxicity in vitro:
Thirty seven studies of validity 2 (published data and reports) were reported in different endpoint study records. Some of them concern in vitro mutation studies in bacteria or mammalian cells, other concern chromosomal aberration studies, with and without metabolic activation system.
Concerning gene mutations, the study report ofHazleton(1991) was selected as key study. This study was conducted according to OECD 471 guideline. The study report of Marzin (1979), as well as published data from Mortelmans (1988), Pool (1982), Ishidate (1984) and Kasamaki (1982) were selected as supporting studies. All these studies were performed with acceptable scientific principles and support the negative results obtained with the key study.
Concerning chromosomal aberrations, the study report ofHazleton(1991) was chosen as key study. The study followed the OECD 473 guideline and was negative.
Other studies reported deal with the antimutagenic effect of Vanillin in gene mutations (Ohta 1986, Watanabe 1988, Sasaki 1987, De Flora 1994), in chromosomal aberrations (Sasaki 1990, Keshava 1997, Tamai 1992) or in micronucleus in vitro on CHO or CHL cells (Keshava 1998). These studies were well conducted and had the validity 2 or 3 according to Klimish.
Ambiguous and some positive results observed in published data were not considered valid because they were not conducted according to recognized guidelines, or were not enough described for assessment. Data concerned sister chromatid exchange and micronucleus in vitro.
CONCLUSION FOR GENOTOXICITY IN VITRO: negative in gene mutations and chromosomal aberrations with and without metabolic activation system.
Genotoxicity in vivo:
One study concerning Vanillin with validity 2 was available and was selected as key study. The summary of this study is the following:
In a OF1 mouse bone marrow micronucleus assay (Marzin, 1979), 10 females per dose were treated by gavage with Vanillin (pure) at doses of 500 and 1000 mg/kg bw. Bone marrow cells were harvested at 6and 30 hours post-treatment. The vehicle was arachid oil.
The positive control induced the appropriate response.
There wereno signs of toxicity during the study.
Four studies on the antimutagenic effect with validity 2, were available and were well described. All of these studies demonstrated that Vanillin had an antimutagenic effect.
CONCLUSION FOR GENOTOXICITY: the in vitro genotoxic studies available indicated negative effects in gene mutations and chromosomal aberrations with and without metabolic activation system. The in vivo studies available on micronucleus assay and antimutagenic effect confirm the absence of genotoxic effect of Vanillin.
All the results available indicated that Vanillin had no effect in genotoxicity studies.According to classification criteria of EC regulation 1272/2008 Vanillin should not be classified for genotoxicity.
Short description of key information:
Vanilline showed negative results in in-vitro studies (Ames test,
chromosomal aberrations) and in in-vivo studies.
Endpoint Conclusion: No adverse effect observed (negative)
Justification for classification or non-classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
